TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1985608

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg daily
Number of subjects: 8245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg daily
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg daily
Number of subjects: 8245
Study: 6878616

Group type: EXPERIMENTAL
Intervention: Health surveillance and health education (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health surveillance (Experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control school
Number of subjects: 0
Study: 30773934

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex®)
Number of subjects: 28
Study: 28903954

Group type: EXPERIMENTAL
Intervention: Casein protein
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 38

Group type: COMPARATOR
Intervention: Maltodextrin (Control)
Number of subjects: 38
Study: 26524815

Group type: EXPERIMENTAL
Intervention: Medical nutrition guidance (EG, n = 124)
Number of subjects: 261
Study: 23375114

Group type: EXPERIMENTAL
Intervention: Recovery Line plus Treatment-as-Usual (TAU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 36
Study: 21107305

Group type: EXPERIMENTAL
Intervention: 2 g mycophenolate mofetil (group A, n=75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 1.440 g enteric-coated mycophenolate sodium (group B, n=75)
Number of subjects: 150
Study: 19008470

Group type: EXPERIMENTAL
Intervention: Folic acid treatment for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid, vitamin B(12), and vitamin B(6) treatment for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble RANKL in vitro
Number of subjects: 0
Study: 16182104

Group type: EXPERIMENTAL
Intervention: Regular red wine (250 mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (250 mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no red wine)
Number of subjects: 15
Study: 12675998

Group type: EXPERIMENTAL
Intervention: FbM (filled by mass)
Number of subjects: 131

Group type: COMPARATOR
Intervention: FbIU (filled by IU)
Number of subjects: 131
Study: 10674881

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg and Megestrol acetate
Number of subjects: 0
Study: 8712136

Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata ≤55 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata 56 to 65 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata 66 to 75 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata >75 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata ≤55 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata 56 to 65 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata 66 to 75 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata >75 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata ≤55 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata 56 to 65 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata 66 to 75 years
Number of subjects: 6676

Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata >75 years
Number of subjects: 6676
Study: 1987807

Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg iv)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6345893

Group type: EXPERIMENTAL
Intervention: Dialyzer clearance of urea (Kd, ml/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of dialysis (Td, hr or min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein intake monitoring (PCR, g/day)
Number of subjects: 0
Study: 31932699

Group type: COMPARATOR
Intervention: Attention Control (AC) group (physical activity recommendations)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High volume of moderate-intensity continuous training
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High-volume and high-intensity interval training (HIIT)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low-volume-HIIT
Number of subjects: 249
Study: 31185374

Group type: EXPERIMENTAL
Intervention: Online TMS to the left superior parietal lobe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active vertex stimulation (control)
Number of subjects: 0
Study: 27668943

Group type: EXPERIMENTAL
Intervention: Full-dose (FD) anticonvulsants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Half-dose (HD) anticonvulsants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stop anticonvulsants
Number of subjects: 36
Study: 27098525

Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Insulin Glargine (IGlar)
Number of subjects: 833
Study: 23346907

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide indirect pulp treatment (CH‐IPT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotic sterilization using a mixture of three antibiotics (3Mix‐MP)
Number of subjects: 50
Study: 23938229

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation plus optimal drug therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Optimal drug therapy
Number of subjects: 30
Study: 18775043

Group type: EXPERIMENTAL
Intervention: Spontaneous diagnostic coved-type ECGs (group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Spontaneous non-diagnostic ECGs (group A)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Drug challenge ECGs (group B)
Number of subjects: 89
Study: 18165484

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 0
Study: 15767153

Group type: EXPERIMENTAL
Intervention: AcrySof MA60BM (Alcon)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sensar AR40 (AMO)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Corneal ACR6D (Corneal Laboratoire)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal phakic eyes (control group)
Number of subjects: 63
Study: 12067328

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (6 MIU once weekly i.m.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9498655

Group type: EXPERIMENTAL
Intervention: Trandolapril 4mg day(-1) (H)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trandolapril 0.5 mg day(-1) (L)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 29
Study: 8530333

Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 2226384

Group type: EXPERIMENTAL
Intervention: Loud voice commands
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal voice commands
Number of subjects: 40
Study: 31847

Group type: EXPERIMENTAL
Intervention: Behavior therapy and imipramine hydrochloride
Number of subjects: 111

Group type: COMPARATOR
Intervention: Behavior therapy and placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy and imipramine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All treatment regimens (including imipramine and placebo) in simple phobic patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Follow-up after one year
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 111
Study: 31484021

Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign® occupational therapy (LR-OT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No-contact comparison group
Number of subjects: 73
Study: 29075347

Group type: EXPERIMENTAL
Intervention: Manual circumference measurement by 6 observers
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: First and second measurements by all observers
Number of subjects: 58
Study: 26113171

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (TPA)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐management Programme (CPSMP)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 141
Study: 23898894

Group type: EXPERIMENTAL
Intervention: Liberal treatment group received one unit of packed red blood cells and as much blood as needed to maintain hemoglobin concentrations at greater than 10 g/dL; median two units of blood received.
Number of subjects: 139

Group type: COMPARATOR
Intervention: Restrictive treatment group received transfusions if they developed symptoms of anemia or their hemoglobin fell below 8 g/dL; median zero units of blood received.
Number of subjects: 139
Study: 21704240

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg in fed state
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after light morning meal
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after light evening meal
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after standard evening meal
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after high-fat evening meal
Number of subjects: 73
Study: 18996650

Group type: EXPERIMENTAL
Intervention: Transvaginal repair of cystocele with mesh
Number of subjects: 6

Group type: COMPARATOR
Intervention: Transvaginal repair of cystocele without mesh
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transvaginal repair of rectocele with mesh
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transvaginal repair of apical prolapse with mesh
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transvaginal repair of POP with mesh
Number of subjects: 6

Group type: COMPARATOR
Intervention: Transvaginal repair of POP without mesh
Number of subjects: 6
Study: 16319918

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then 30 mg/day for 2 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Paroxetine (various doses)
Number of subjects: 62
Study: 12177026

Group type: EXPERIMENTAL
Intervention: Brief negotiation
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Direct advice
Number of subjects: 1658

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1658
Study: 10459684

Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam (TRZ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7608255

Group type: EXPERIMENTAL
Intervention: Metformin administration (850 mg, twice daily for 4 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low calorie diet (1500 Cal/day)
Number of subjects: 24
Study: 2404483

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 358763

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (BFT), 10 mg, given orally after fasting overnight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bendroflumethiazide (BFT), 10 mg, given orally together with a meal
Number of subjects: 8
Study: 29634987

Group type: EXPERIMENTAL
Intervention: Category average reference point (CARP) provided by a credible source
Number of subjects: 698

Group type: COMPARATOR
Intervention: Category average reference point (CARP)
Number of subjects: 698
Study: 25125244

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 21
Study: 25323335

Group type: EXPERIMENTAL
Intervention: Oxymizer
Number of subjects: 43

Group type: COMPARATOR
Intervention: CNC
Number of subjects: 43
Study: 23085128

Group type: EXPERIMENTAL
Intervention: 0 ICD shocks during DFT testing
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: 1 ICD shock during DFT testing
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: 2 ICD shocks during DFT testing
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: 3 or more ICD shocks during DFT testing
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: High-energy ICD shocks (>20 J)
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Low-energy ICD shocks (≤20 J)
Number of subjects: 1659
Study: 20586675

Group type: EXPERIMENTAL
Intervention: Remote programming
Number of subjects: 70

Group type: COMPARATOR
Intervention: Face-to-face programming
Number of subjects: 70
Study: 18802184

Group type: EXPERIMENTAL
Intervention: Standard drug counseling
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Motivational interviewing/skills-building therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Incentives for attending sessions and submitting marijuana-free urine specimens
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Quiz scores
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study: 16007412

Group type: EXPERIMENTAL
Intervention: S21403 (mitiglinide) 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12407036

Group type: EXPERIMENTAL
Intervention: Fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualized single dose protocol (group 3)
Number of subjects: 60
Study: 9802369

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 46
Study: 7618619

Group type: EXPERIMENTAL
Intervention: Captopril (150 mg/day in 3 separate doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2794181

Group type: EXPERIMENTAL
Intervention: Computerized nicotine fading and stop‐smoking contest
Number of subjects: 58

Group type: COMPARATOR
Intervention: Contest‐only group
Number of subjects: 58
Study: 414272

Group type: EXPERIMENTAL
Intervention: Alcohol state (1.0 ml/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sober state
Number of subjects: 28
Study: 31601250

Group type: EXPERIMENTAL
Intervention: Social group intervention (sensitization/education of social groups about MRDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social group/provider intervention (social group treatment plus training of healthcare providers in health communication about MRDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (usual practice of provision of MRDT services by public primary healthcare providers and patent medicine vendors)
Number of subjects: 0
Study: 28657701

Group type: EXPERIMENTAL
Intervention: Stabilized SnF2 dentifrice
Number of subjects: 40
Study: 25491347

Group type: EXPERIMENTAL
Intervention: 20 mg zinc as zinc sulfate daily for 17 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23663094

Group type: EXPERIMENTAL
Intervention: Licorice (1140 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogen 0.312 mg/day and Medroxyprogesterone 2.5 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 60
Study: 22898579

Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ in multiplayer mode
Number of subjects: 14

Group type: COMPARATOR
Intervention: Xbox Kinect™
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wii™ in multiplayer mode
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wii™
Number of subjects: 14
Study: 19192469

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 314

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Aripiprazole (white subjects)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Olanzapine (black/Hispanic subjects)
Number of subjects: 314
Study: 17918451

Group type: EXPERIMENTAL
Intervention: Bie Jia Jian
Number of subjects: 98

Group type: COMPARATOR
Intervention: Western medicine for liver protection
Number of subjects: 98
Study: 15121738

Group type: EXPERIMENTAL
Intervention: Heliox (80% helium, 20% oxygen)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single-path trumpet model considering axial diffusion
Number of subjects: 9
Study: 11590989

Group type: EXPERIMENTAL
Intervention: Heated olive oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heated safflower oil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (fasting state)
Number of subjects: 14
Study: 9677769

Group type: EXPERIMENTAL
Intervention: Group A (59 procedures by an experienced surgeon)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Group B (47 procedures by residents with less than ten cases experience)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Group C (20 procedures by residents with at least 5 tension-free repairs experience)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 106
Study: 7928829

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin modified release (MR) 100 mg bd
Number of subjects: 538

Group type: COMPARATOR
Intervention: Co-trimoxazole 960 mg bd
Number of subjects: 538

Group type: COMPARATOR
Intervention: Trimethoprim 200 mg bd
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin MR
Number of subjects: 538

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 538

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 538
Study: 29937267

Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg or 100 mg daily)
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 27668546

Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx (Xtampza ER) administered sprinkled onto soft foods or via enteral feeding tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx (Xtampza ER)
Number of subjects: 0
Study: 25144697

Group type: EXPERIMENTAL
Intervention: Cancer survival skills training for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 23746376

Group type: EXPERIMENTAL
Intervention: eGFR ≤29 mL/min/1.73 m²
Number of subjects: 5805

Group type: COMPARATOR
Intervention: eGFR categories (75‐89, 60‐74, 45‐59, 30‐44)
Number of subjects: 5805

Group type: COMPARATOR
Intervention: eGFR ≥90 mL/min/1.73 m²
Number of subjects: 5805
Study: 20186426

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 24
Study: 19690125

Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 205

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 205
Study: 16970531

Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 30 seconds
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 60 seconds
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 180 seconds
Number of subjects: 18
Study: 14629635

Group type: EXPERIMENTAL
Intervention: Introduction of 'pain-advisers' in the study area (SA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control area (CA) without 'pain-advisers'
Number of subjects: 53
Study: 10644899

Group type: EXPERIMENTAL
Intervention: Estradiol patches (Estraderm TTS; 0.8 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Estradiol alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH; 10 mg p.o.)
Number of subjects: 2
Study: 9288292

Group type: EXPERIMENTAL
Intervention: Nasal provocation test with ammonium persulphate (APS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal provocation test with dandruff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo nasal provocation test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal provocation test with ammonium thioglycolate (ATG)
Number of subjects: 40
Study: 7689827

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 267

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 267
Study: 3463727

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1% zinc citrate and 0.5% 2,4,4' trichloro-2'-hydroxydiphenyl ether
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30185583

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy alone
Number of subjects: 600

Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC) oxygen therapy with non-invasive ventilation (NIV) sessions
Number of subjects: 600
Study: 26655425

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (90 mg/m2 on days 1 and 2, rituximab 375 mg/m2 on day 1)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fludarabine plus rituximab (25 mg/m2 on days 1-3, rituximab 375 mg/m2 on day 1)
Number of subjects: 219
Study: 25001947

Group type: EXPERIMENTAL
Intervention: sublingual melatonin 3 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: sublingual melatonin 10 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: sublingual placebo
Number of subjects: 99
Study: 22543913

Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening using algorithms to interpret CA125 and ultrasound imaging
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening with well-defined, centrally coordinated management of screen-detected abnormalities
Number of subjects: 202638